3-Boc-氨基-2-哌啶乙酸乙酯 | 215306-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-Boc-氨基-2-哌啶乙酸乙酯
• 英文名称: ethyl {3-[(tert-butoxycarbonyl)amino]piperidin-2-yl}acetate
• 英文别名: ethyl {(2RS,3SR)-3-[(tert-butoxycarbonyl)amino]piperidin-2-yl}acetate；Ethyl 2-(3-((tert-butoxycarbonyl)amino)piperidin-2-yl)acetate；ethyl 2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-2-yl]acetate
• CAS: 215306-00-6
• 化学式: C₁₄H₂₆N₂O₄
• 分子量: 286.371
• InChiKey: JWIFFLUEVLMGJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Boc-氨基-2-哌啶乙酸乙酯 、 氯甲酸苄酯 在 sodium tetrahydroborate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 16.5h， 生成 benzyl trans-3-amino-2-(2-hydroxyethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2006/106326

  摘要：

  公开号：

文献信息

• NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Ochiai Hiroshi

  公开号：US20090233908A1

  公开（公告）日：2009-09-17

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为（I）：（其中符号的定义与说明书中相同），其盐，N-氧化物，溶剂化合物或前药，以及其药用。化合物（I）具有CXCR4拮抗活性。因此，它可用作预防和/或治疗CXCR4介导疾病的药物，例如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应），过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗剂。
• SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS
  申请人：Daly Kevin

  公开号：US20090275570A1

  公开（公告）日：2009-11-05

  The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

  本发明涉及新的化合物（I）及其药物组成物和使用方法。这些新的化合物具有CHK1激酶抑制活性，PDK1抑制活性和Pak激酶抑制活性，因此在癌症的治疗和/或预防中有用。
• Nitrogenous heterocyclic compound and medicinal use thereof
  申请人：Ochiai Hiroshi

  公开号：US08680092B2

  公开（公告）日：2014-03-25

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为(I):(其中符号的定义与说明中相同)，其盐、N-氧化物、溶剂合物或前药，以及其药用。化合物(I)具有CXCR4拮抗活性。因此，它可用作CXCR4介导疾病（例如类风湿性关节炎、关节炎、视网膜病变、肺纤维化、移植器官排斥反应等炎症/免疫疾病，过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心脏/血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗的药物。